HU9502720D0 - Process for preparing cancer vaccines - Google Patents

Process for preparing cancer vaccines

Info

Publication number
HU9502720D0
HU9502720D0 HU9502720A HU9502720A HU9502720D0 HU 9502720 D0 HU9502720 D0 HU 9502720D0 HU 9502720 A HU9502720 A HU 9502720A HU 9502720 A HU9502720 A HU 9502720A HU 9502720 D0 HU9502720 D0 HU 9502720D0
Authority
HU
Hungary
Prior art keywords
cancer vaccines
preparing cancer
preparing
vaccines
cancer
Prior art date
Application number
HU9502720A
Other languages
Hungarian (hu)
Other versions
HUT73383A (en
Inventor
Michael Buschle
Matthew Cotten
Gerhard Maas
Gotthold Schaffner
Max L Birnstiel
Christian Plank
Walter Schmidt
Ernst Wagner
Kurt Zatloukal
Original Assignee
Genentech Inc
Boehringer Sohn Ingelheim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0055693A external-priority patent/AT399656B/en
Priority claimed from DE4326821A external-priority patent/DE4326821A1/en
Application filed by Genentech Inc, Boehringer Sohn Ingelheim filed Critical Genentech Inc
Publication of HU9502720D0 publication Critical patent/HU9502720D0/en
Publication of HUT73383A publication Critical patent/HUT73383A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HU9502720A 1993-03-19 1994-03-18 Process for preparing cancer vaccines HUT73383A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0055693A AT399656B (en) 1993-03-19 1993-03-19 Process for the production of cancer vaccines
DE4326821A DE4326821A1 (en) 1993-08-10 1993-08-10 New cancer vaccine based on autologous, transfected tumour cells

Publications (2)

Publication Number Publication Date
HU9502720D0 true HU9502720D0 (en) 1995-11-28
HUT73383A HUT73383A (en) 1996-07-29

Family

ID=25593140

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9502720A HUT73383A (en) 1993-03-19 1994-03-18 Process for preparing cancer vaccines

Country Status (13)

Country Link
EP (1) EP0689604A1 (en)
JP (1) JPH08507921A (en)
KR (1) KR960701211A (en)
CN (1) CN1119459A (en)
AU (1) AU6427994A (en)
CA (1) CA2158655A1 (en)
CZ (1) CZ241795A3 (en)
FI (1) FI954383A0 (en)
HU (1) HUT73383A (en)
NO (1) NO953684L (en)
NZ (1) NZ263550A (en)
PL (1) PL311036A1 (en)
WO (1) WO1994021808A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2190290C (en) * 1994-05-13 2011-07-05 Michael J. Mastrangelo A method of inducing an immune response using vaccinia virus recombinants
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
DE4426429A1 (en) * 1994-07-26 1996-02-01 Boehringer Ingelheim Int Method for introducing DNA into higher eukaryotic cells
DE19510344C1 (en) * 1995-03-22 1996-11-07 Boehringer Ingelheim Int Use of a tumor vaccine
AU6282896A (en) * 1995-06-19 1997-01-15 University Of Medicine And Dentistry Of New Jersey Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins
DE19608751B4 (en) 1996-03-06 2006-05-18 Medigene Ag Use of an adeno-associated virus vector to increase the immunogenicity of cells
DE19608753C1 (en) * 1996-03-06 1997-06-26 Medigene Gmbh Transduction system based on rep-negative adeno-associated virus vector
US7001765B2 (en) 1996-03-06 2006-02-21 Medigene Ag Adeno-associated virus vector for boosting immunogenicity of cells
DE19631357A1 (en) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vector for activating the immune system against cells associated with papilloma viruses or sequences thereof
KR20010022863A (en) * 1997-08-13 2001-03-26 피터 브이. 오`네일 Vaccination by topical application of genetic vectors
WO1999008997A1 (en) 1997-08-13 1999-02-25 Biontex Laboratories Gmbh Novel lipopolyamines, and the preparation and use thereof
US7348015B2 (en) 1998-01-14 2008-03-25 Morphogenesis, Inc. Antigen modified cancer cell vaccines for cancer therapy
WO1999036433A2 (en) 1998-01-14 1999-07-22 Morphogenesis, Inc. Materials and methods for treating oncological disease
US7795020B2 (en) 1998-01-14 2010-09-14 Morphogenesis, Inc. Tumor cell vaccines
EP1829551B1 (en) * 1998-02-20 2010-09-29 University of Miami Modified heat shock protein-antigenic peptide complex
DE60040213D1 (en) 1999-02-09 2008-10-23 Riken Wako TUMOR VACCINE
BR0001029A (en) * 2000-04-10 2001-11-20 Fk Biotecnologia Ltda Process of transformation of tumor cells
AUPQ755300A0 (en) 2000-05-17 2000-06-08 Monash University Immune potentiating compositions
DE10131148A1 (en) * 2001-06-28 2003-01-16 I P L Internat Pharmaceutics L Xenogenic oligo- and / or polyribonucleotides as agents for the treatment of malignant tumors
US7176022B2 (en) * 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
CN102014937A (en) 2008-03-03 2011-04-13 迈阿密大学 Allogeneic cancer cell-based immunotherapy
JP2011515399A (en) 2008-03-20 2011-05-19 ユニバーシティー オブ マイアミ Heat shock protein GP96 vaccination and method using the same
SG10201509823WA (en) * 2010-12-02 2015-12-30 Oncotherapy Science Inc TOMM34 Peptides And Vaccines Including The Same
WO2016127015A1 (en) 2015-02-06 2016-08-11 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
US11273170B2 (en) * 2016-07-25 2022-03-15 Ascend Biopharmaceuticals Ltd Methods of treating cancer
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
WO2019132594A1 (en) * 2017-12-29 2019-07-04 한양대학교 산학협력단 Cell sheet for gene delivery

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation

Also Published As

Publication number Publication date
HUT73383A (en) 1996-07-29
CA2158655A1 (en) 1994-09-29
NZ263550A (en) 1996-12-20
NO953684D0 (en) 1995-09-18
FI954383A (en) 1995-09-18
EP0689604A1 (en) 1996-01-03
PL311036A1 (en) 1996-01-22
NO953684L (en) 1995-09-18
CN1119459A (en) 1996-03-27
KR960701211A (en) 1996-02-24
JPH08507921A (en) 1996-08-27
AU6427994A (en) 1994-10-11
WO1994021808A1 (en) 1994-09-29
FI954383A0 (en) 1995-09-18
CZ241795A3 (en) 1996-04-17

Similar Documents

Publication Publication Date Title
HU9502720D0 (en) Process for preparing cancer vaccines
SG55048A1 (en) Process for preparing 2-para-dioxanones
GB2257149B (en) Process for preparing polyoxyalkylene- or alkylpolyglucoside- carboxylates
EP0481297A3 (en) Process for preparing polyisobutylene
HU912375D0 (en) Process for producing preparatives against tumour
YU67290A (en) Process for preparing cephodizim-disodium
CS324791A3 (en) Process for preparing kerebastin
IL107698A0 (en) Process for preparing immunoconjugates
CS266691A3 (en) Process for preparing peptides
EP0503294A3 (en) Process for preparing perfluorpolyetheracrylfluorides
PH31154A (en) Process for preparing 1-alkylryl-2-alkyl-5-formyl-imidazole.
AU6847590A (en) Process for preparing pentafluorodichloropropanes
EP0461597A3 (en) Method for preparing monohalogenosilanes
HU9600659D0 (en) Process for preparing cyclic cis-1-amino-2-alkanols
ZA925560B (en) Process for preparing 13alpha-cinnamoyl-baccatine iii or-10-deacetyl-baccatine iii
CS180792A3 (en) Process for preparing phenol
IL103261A0 (en) Process for preparing 4-chlorobenzotrichloride
IL104398A0 (en) Process for preparing substituted 2-cyanopyridines
LTIP1745A (en) Process for preparing 5-arginylaminonaphthalene-1-sulphamides
LTIP1741A (en) Process for preparing 5-aminonaphthalene-1-sulphamides
EP0644193A3 (en) Process for preparing 2-acetylamino-6-chloropurine.
EP0433888A3 (en) Process for preparing polyalkylenglycolbisethers
EP0545682A3 (en) Process for preparing alpha-chloro-alpha-oximino-4-hydroxyacetophenone
FI103115B1 (en) Process for preparing 2-chloromethylsaccharin
CS513590A3 (en) Process for preparing hydantoin-5-spirocyclopentane

Legal Events

Date Code Title Description
DFD9 Temporary protection cancelled due to non-payment of fee